Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma

NCT06264778 is registered in ClinicalTrials.gov with Shandong University as lead sponsor.

NCT NCT06264778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06264778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma
Lead sponsor
Shandong University
Phase
Phase 3
Overall status
Unknown status
Start date
March 1, 2024
Completion date
December 31, 2025
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ameloblastoma